NUCYNTA
TAPENTADOL HYDROCHLORIDE
Approval overview NUCYNTA is listed in Drugs@FDA under application 203794 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient TAPENTADOL HYDROCHLORIDE Form and strength SOLUTION;ORAL - EQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor COLLEGIUM PHARM INC Submission history Latest submission status date: 2025-12-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview NUCYNTA is listed in Drugs@FDA under application 203794 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TAPENTADOL HYDROCHLORIDE Form and strength SOLUTION;ORAL - EQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor COLLEGIUM PHARM INC Submission history Latest submission status date: 2025-12-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.